Neoparin Multi (Enoxaparin Sodium)

Enoxaparin Sodium is a low molecular weight heparin used in the prevention and treatment of venous thrombo‑embolism.

• Deep vein thrombosis (DVT) prophylaxis in surgical patients: reduces the incidence of postoperative clot formation.
• Acute deep vein thrombosis treatment: facilitates clot resolution and prevents extension.
• Pulmonary embolism prevention and treatment: lowers the risk of life‑threatening embolic events.
• Anticoagulation during haemodialysis: maintains circuit patency and prevents clotting during treatment.

• Enoxaparin Sodium potentiates antithrombin III, enhancing its inhibition of activated factor Xa and, to a lesser extent, factor IIa (thrombin). This selective blockade reduces thrombin generation and fibrin clot formation while preserving a degree of platelet function, providing effective anticoagulation with a more predictable pharmacokinetic profile than unfractionated heparin.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Injection site pain or erythema: mild discomfort at the administration site.
• Bruising or hematoma: localized bleeding under the skin.
• Nausea or vomiting: gastrointestinal upset.
• Headache or dizziness: transient neurologic symptoms.
• Mild bleeding (e.g., gum, epistaxis): minor hemorrhagic events.

Serious or Rare Side Effects

• Major bleeding: internal hemorrhage requiring medical intervention.
• Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Skin necrosis at injection sites: severe local tissue damage.
• Spinal or epidural hematoma: rare but serious neurologic complication.
• Elevated liver enzymes: abnormal hepatic function tests.

Careful assessment is required before initiating therapy with Enoxaparin Sodium.

• Renal impairment: dose adjustment may be needed in patients with reduced clearance.
• Hepatic disease: monitor coagulation parameters in severe liver dysfunction.
• Concomitant anticoagulants or antiplatelet agents: increased bleeding risk.
• Recent surgery or trauma: evaluate bleeding risk before administration.
• Pregnancy and breastfeeding: safety not established; use only if benefits outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin Sodium can interact with several drug classes, influencing bleeding risk or anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, direct thrombin inhibitors): additive anticoagulation.
• Antiplatelet drugs (e.g., aspirin, clopidogrel): heightened hemorrhagic potential.
• Fibrinolytic agents (e.g., alteplase): synergistic clot‑dissolving effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased mucosal bleeding.
• Spinal or epidural anesthesia: risk of spinal hematoma.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: possible additive hypotensive effect.
• Diuretics: monitor renal function and electrolytes.
• Certain antibiotics (e.g., vancomycin, quinolones): may alter platelet function.
• Hormonal contraceptives: modest increase in thrombotic risk.
• Lipid‑lowering agents (e.g., statins): monitor for rare bleeding events.